Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21204651 | 0.90 | DPP4 (0.37) | PIK3CDMAPTDPP4DPP8DPP9 | |
| SCHEMBL8301445 | 0.82 | PIK3CD (0.41) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL26352077 | 0.80 | HPGD (0.48) | MAPTEPHX1DPP4 | |
| SCHEMBL21204571 | 0.79 | PIK3CD (0.34) | PIK3CDMAPTDPP4DPP8DPP9 | |
| SCHEMBL19322325 | 0.77 | PIK3CD (0.37) | PIK3CDCYP1A2TDP1 | |
| SCHEMBL14403745 | 0.77 | EPHX2 (0.41) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL23133949 | 0.76 | HTR4 (0.42) | PIK3CDMAPT | |
| SCHEMBL21311517 | 0.76 | HRH3 (0.44) | — | |
| SCHEMBL6379934 | 0.74 | — | — | |
| SCHEMBL11915746 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME LLC (US) | 2023-02-23 | — | — | US | disclosed |
| US-10787434-B2 | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY, LTD (AU) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787434-B2 | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBG2, HBZ | PIK3CD 3459/4885MAPT 4850/4885EPHX2 1192/4885 |
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | ZC3HAV1, HDAC11, CXCR1 | PIK3CD 3374/4885MAPT 3926/4885EPHX2 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.